Insys Therapeutics (INSY) Receives Daily News Impact Score of 0.02
News coverage about Insys Therapeutics (NASDAQ:INSY) has trended somewhat positive this week, Accern Sentiment reports. The research group rates the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Insys Therapeutics earned a news impact score of 0.02 on Accern’s scale. Accern also gave media coverage about the specialty pharmaceutical company an impact score of 44.824684512907 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the news headlines that may have impacted Accern Sentiment’s rankings:
- Health Brief: Some Moderate House Democrats Seek ACA Stabilization (morningconsult.com)
- Big Pharma Company Caught Faking Cancer Patients To Sell Deadly Opioid Drugs – Collective Evolution (collective-evolution.com)
- Exclusive: Prosecutors identify Insys founder as unindicted co-conspirator in opioid case – Reuters (reuters.com)
- Teva Looks to Hit Insys Where It Hurts – Seeking Alpha (seekingalpha.com)
- Company under fire for opioid marketing files patent suit (finance.yahoo.com)
Shares of Insys Therapeutics (INSY) traded down 1.30% on Monday, reaching $9.10. 126,776 shares of the company’s stock were exchanged. Insys Therapeutics has a 12 month low of $8.70 and a 12 month high of $15.06. The company’s market capitalization is $661.53 million. The firm’s 50 day moving average price is $9.58 and its 200-day moving average price is $11.21.
Insys Therapeutics (NASDAQ:INSY) last announced its quarterly earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported $0.03 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.09) by $0.12. The business had revenue of $42.60 million during the quarter, compared to analysts’ expectations of $36.90 million. Insys Therapeutics had a negative return on equity of 3.02% and a negative net margin of 9.63%. The firm’s quarterly revenue was down 38.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.13 EPS. On average, equities analysts anticipate that Insys Therapeutics will post ($0.29) EPS for the current year.
INSY has been the topic of several analyst reports. Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of Insys Therapeutics in a research note on Thursday, August 3rd. Royal Bank Of Canada set a $16.00 target price on shares of Insys Therapeutics and gave the stock a “buy” rating in a research report on Saturday, June 3rd. TheStreet cut shares of Insys Therapeutics from a “c-” rating to a “d+” rating in a research report on Monday, August 21st. Zacks Investment Research raised shares of Insys Therapeutics from a “sell” rating to a “strong-buy” rating and set a $15.00 target price on the stock in a research report on Wednesday, July 12th. Finally, BidaskClub cut shares of Insys Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $13.25.
In other news, CEO Saeed Motahari purchased 5,500 shares of the stock in a transaction that occurred on Thursday, August 10th. The stock was acquired at an average price of $8.92 per share, with a total value of $49,060.00. Following the purchase, the chief executive officer now owns 15,400 shares in the company, valued at approximately $137,368. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder John N. Kapoor Trust Dated Sept purchased 17,500 shares of the stock in a transaction that occurred on Friday, August 11th. The stock was purchased at an average cost of $8.93 per share, with a total value of $156,275.00. Following the purchase, the insider now owns 31,982 shares in the company, valued at approximately $285,599.26. The disclosure for this purchase can be found here. Insiders own 67.90% of the company’s stock.
Insys Therapeutics Company Profile
Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.
Receive News & Stock Ratings for Insys Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics Inc. and related stocks with our FREE daily email newsletter.